Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 16/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.71 |
| ▸ | TMIGD3 | P0DMS9 | 4/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25566632 | 0.84 | ADORA3 (0.53) | ADORA3ADORA1TMIGD3ADORA2A | |
| SCHEMBL21940221 | 0.84 | ADORA3 (0.75) | ADORA3ADORA1TMIGD3ADORA2AHTR2B | |
| SCHEMBL16774258 | 0.83 | ADORA3 (1.00) | ADORA3ADORA1TMIGD3ADORA2A | |
| SCHEMBL16774370 | 0.83 | ADORA3 (1.00) | ADORA3ADORA1TMIGD3ADORA2A | |
| SCHEMBL20122135 | 0.79 | ADORA3 (0.76) | ADORA3ADORA1TMIGD3ADORA2AHTR2C | |
| SCHEMBL19503864 | 0.79 | ADORA3 (0.69) | ADORA3ADORA1TMIGD3ADORA2AHTR2C | |
| SCHEMBL19503865 | 0.78 | ADORA3 (0.76) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL17243941 | 0.78 | ADORA3 (0.60) | ADORA3ADORA1TMIGD3ADORA2AHTR2C | |
| SCHEMBL19807422 | 0.76 | ADORA3 (0.75) | ADORA3ADORA1TMIGD3ADORA2AHTR2C | |
| SCHEMBL25566672 | 0.75 | AHCY (0.56) | ADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091791-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |